Posts

Showing posts from April, 2024

QMSR Guide: FDA 21 CFR 820 & ISO 13485 Harmonization 2026

Image
QMSR Transition: Harmonizing FDA 21 CFR 820 with ISO 13485:2016— Post-Implementation Guide 2026 A Post-Implementation Compliance and Inspection Readiness Guide for Medical Device Manufacturers — April 2026 Updated April 2026  |  18-minute read  |  Sourced from FDA.gov, Federal Register, and peer-reviewed regulatory guidance 📋 Table of Contents The Day the QSR Died — and What That Means for You Right Now Why the FDA Finally Made This Move Incorporation by Reference: What It Actually Means in Practice The Terminology Shift: A Complete Comparison Table ISO 14971 and Risk Management: The Connective Tissue of the New QMS Design and Development: The Most Substantive Change You May Have Missed The End of QSIT — What CP 7382.850 Means for Your Next Inspection The Records FDA Can Now See That It Couldn't Before MDSAP, ISO Certification, and the Global Harmonization Play 5-Point Compliance Che...

Alembic seeks to mix it with US and European players

Alembic seeks to mix it with US and European players Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme.  The Gujarat-headquartered group, which is involved in both the active pharmaceutical ingredient (API) and pharmaceutical formulation markets, aims to grow internationally and double its annual turnover over the next two to three years, according to a report in India’s Business Standard. Company director Pranav Amin explained that the firm intends to file about 10-12 ANDAs every year and to tap potential in the generic markets of the US and Europe.  The company has also submitted around 22 drug master file (DMF) requests to regulatory agencies in Europe and the US in recent years in a bid to boost its roster of API clients.